www.sisaf.com Open in urlscan Pro
82.145.60.154  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About Us
   * SiSaf
   * Our History
   * Management Team
   * Advisors
   * Board
 * Science
   * Bio-Courier technology
   * RNA Delivery
   * Publications
 * Pipeline
   * Pipeline Summary
   * Osteopetrosis
   * Achondroplasia
   * Corneal Dystrophy
 * Partners
 * News & Events
   * Press Releases
   * In the News
   * Events
 * Contact Us

Show Menu
Menu



DELIVERING ON THE PROMISE OF RNA THERAPEUTICS

SiSaf is an RNA delivery and therapeutics company.

Our proprietary Bio-Courier® technology addresses the limitations of other RNA
delivery technologies through the hybridization of organic materials with
inorganic bioabsorbable silicon.

We are advancing a first-in-class pipeline of RNA therapeutics for rare and
currently incurable autosomal dominant diseases of the bone and eye, alongside
partnering with others to maximise the value Bio-Courier technology brings to
RNA therapeutics and vaccines.


OUR SCIENCE

Our silicon-stabilized hybrid lipid nanoparticles (sshLNPTM) improve the
stability, safety, and transfection efficiency of RNA.

Learn more


PIPELINE

We are developing a growing pipeline of RNA therapeutics for rare diseases

Learn more


PARTNERING

We are partnering with leaders in the field of RNA therapeutics

Learn more


NEWS

Previous

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal
epithelium

More

SiSaf announces licencing agreement to develop gene therapy for rare bone
disease

More

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

More

SiSaf Establishes Strategic Partnership with Avellino Labs

More

RNA Delivery and Therapeutics Company SiSaf Announces Autumn Conference Schedule

More

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat
Rare Genetic Bone Disorder Osteopetrosis

More

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

More

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone
Disease, as Clinical Advisor

More

SiSaf exercises its option under licencing agreement on gene therapy for rare
bone disease

More

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

More

SiSaf Ltd Announces US$13.2 Million Series B Financing

More

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal
epithelium

More

SiSaf announces licencing agreement to develop gene therapy for rare bone
disease

More

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

More

SiSaf Establishes Strategic Partnership with Avellino Labs

More

RNA Delivery and Therapeutics Company SiSaf Announces Autumn Conference Schedule

More

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat
Rare Genetic Bone Disorder Osteopetrosis

More

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

More

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone
Disease, as Clinical Advisor

More
Next

Contact SiSaf Ltd

+44 1483 912002 | info@sisaf.com

SiSaf © 2022

Terms and Conditions

Privacy Policy

FIND US

LONDON | BELFAST

We use cookies on our website to give you the most relevant experience by
remembering your preferences and repeat visits. By clicking “Accept All”, you
consent to the use of ALL the cookies. However, you may visit "Cookie Settings"
to provide a controlled consent.
Cookie SettingsAccept All
Manage consent
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
These cookies ensure basic functionalities and security features of the website,
anonymously.

CookieDurationDescriptioncookielawinfo-checkbox-analytics11 monthsThis cookie is
set by GDPR Cookie Consent plugin. The cookie is used to store the user consent
for the cookies in the category "Analytics".cookielawinfo-checkbox-functional11
monthsThe cookie is set by GDPR cookie consent to record the user consent for
the cookies in the category "Functional".cookielawinfo-checkbox-necessary11
monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to
store the user consent for the cookies in the category
"Necessary".cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookie is used to store the user consent for the
cookies in the category "Other.cookielawinfo-checkbox-performance11 monthsThis
cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the
user consent for the cookies in the category
"Performance".viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie
Consent plugin and is used to store whether or not user has consented to the use
of cookies. It does not store any personal data.

Functional
Functional
Functional cookies help to perform certain functionalities like sharing the
content of the website on social media platforms, collect feedbacks, and other
third-party features.
Performance
Performance
Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.
Analytics
Analytics
Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics the number of
visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and
marketing campaigns. These cookies track visitors across websites and collect
information to provide customized ads.
Others
Others
Other uncategorized cookies are those that are being analyzed and have not been
classified into a category as yet.
SAVE & ACCEPT